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Objective: To evaluate the presentation and outcome of imported malaria. 
Patients and methods: Retrospective charts review of hospitalized patients with smear-proven malaria from January 
1989 to October 1994. 
Results: Of a total of 111 cases, 95 were caused by Plasmodium falciparum. Chemoprophylaxis was used in  57% of 
patients but only 41% were compliant. Parasitemia ranged from 0.1% to 22%. Clinical and biological signs at admission 
were unspecific. In all cases where both platelets and C-reactive protein were measured, at least one abnormality was 
noted. More than two WHO gravity criteria were present in 14 cases. Outcome was marked by two deaths and 18 adverse 
drug reactions. PIasmodium falciparum was associated to only one independent factor in multivariate analysis: symptom 
onset less than 30 days after return. Chemoprophylaxis use did not modify clinical presentation, mean parasitemia or 
outcome. 
Conclusions: f! fakiparum is the most usual cause of imported malaria in  France. Normal platelet count and C-reactive 
protein value probably exclude the diagnosis of malaria in  febrile travelers. 
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INTRODUCTION 
Malaria is a leading cause of morbidity and mortality in 
tropical countries [ 11. Incidence in travelers from 
Western countries has dramatically increased over 
the years [2-41 due to multiple factors: development 
of tourism, extension of drug-resistant Plasmodium 
fakiparum, inappropriate chemoprophylaxis or low 
compliance [2,3]. Our objectives were to (1) evaluate 
the presentation and outcome of malaria in non- 
immune subjects, (2) evaluate the influence of chemo- 
prophylaxis and (3)  identifj. signs associated with I? 
fakiparum or a high parasitemia. 
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PATIENTS AND METHODS 
We conducted a retrospective charts review of all adult 
patients hospitalized in our departments from January 
1989 to October 1994 and presenting with a positive 
thin or thick smear. Nine patients, initially admitted in 
the intensive care unit (ICU), were part of a previous 
report [5]. The department of Infectious Diseases is the 
reference center of a 1.5-million population and, like 
the ICU, is part of a university-affiliated 500-bed 
hospital. Recorded variables were: age, sex, chemo- 
prophylaxis use, visited country, clinical and biological 
signs at admission, therapy and outcome. Severe malaria 
was defined according to the W H O  criteria [6] .  Tourists 
were defined as persons living in non-malaria-endemic 
countries for more than 10 years and staying in a 
malaria-endemic area for less than 3 months. Expatriates 
were defined as persons originating from a malaria-free 
area and living in a malaria-endemic area for more than 
1 year. No sensitivity testing of Plasmodium spp. to anti- 
malarial drugs was available. 
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Table 1 Prophylaxis use, compliance and chloroquine 
resistance in travel area among 111 patients with 
imported malaria 
Prophylaxis Total users Resistance 
Low compliance (n) (none, low or high) 
Cldoi-oquine 47 34 low, 13  high 
12 9 low, 3 high 
Chloroquine/ 14 8 low, 6 high 
proguanil 4 4 low 
Mcfloquine 1 1 low 
1 1 low 
Sulfadoxine/ 1 1 low 
None 48 2 none, 34 low, 
pyrimethamine 
12 high 
Statistical methods 
Discrete variables were compared with chi-squared 
or Fisher's exact test and continuous variables with 
Wilcoxon rank sum test. All significant values in mono- 
variate analysis were submitted to a multivariate analysis 
using canonical discriminant analysis [7] which deter- 
mined independent factors and assigned for each one a 
value directly proportional to the magnitude of its 
coefficient. Values >0.4 were considered as indepen- 
dently significant. The EPI info 5.0 (CDC, Atlanta, 
GA, USA) and SAS (SAS Institute Inc., Cary NC,  
USA) statistical softwares packages were used. All p 
values are two-tailed. 
Among 153 patients discharged with a diagnosis of 
malaria, 27 had a negative admission smear following 
previous therapy, and 15 were residents of malaria- 
endemic countries. Thus, l l l patients were available 
for analysis including 86 tourists, 34 of whom were 
foreign born but had been living in France for more 
than 10 years, and 25 expatriates. 
Biographical data 
Seventy-two patients were men and 38 were women. 
Their mean age was 30213  years (range 15 to 79). 
Prophylaxis was used by 63 (57%) patients (Table 1). 
They had traveled to West Africa (n= 57), Central Africa 
(n=38), East Africa (n=3), South America ( ~ = 1 0 ) ,  or 
Asia (n=3). The mean tourist travel duration was 
37.8k28.7 days (range 4 to 90), with 49% under 3 
weeks. The mean time to symptom onset after return 
was 44286 days. Symptoms developed while still in 
the endemic area in 19 patients (17%). The mean time 
between symptom onset and therapy, 6.726.8 days, was 
similar whatever prophylaxis was used. Previous malaria 
episodes were documented in 18 expatriates and 
25 tourists (p<0.0006). Mean body temperature at  
admission was 39.3k 1.1 "C. Clinical signs at admission 
and W H O  gravity criteria are summarized in Table 2. 
Only 14 patients presented more than two criteria. 
Biological parameters are shown in Table 3. C-reactive 
protein (CRP) was >8  mg/L and/or platelets were 
< 100,000/nim3 in all explored patients. Twelve 
patients, nine using chloroquine, were treated for 
dengue, influenza or bacterial infections before malaria 
diagnosis, resulting in treatment delay (9.4 versus 6.7 
days) and higher symptom frequency. 
PI fakiparum 
I? falcipavum was present in 95 cases, including 89 
acquired in Africa. J? vivax was observed in 12 cases, 
including four mixed with l? falcipavum, J? malariae and 
l? ovale in one case each. Parameters associated with I? 
fakiparum in monovariate analysis were: a shorter time 
to symptom onset (25.6k53.7 versus 177.8k129.5 
Table 2 Admission symptoms and WHO gravity criteria (6) of patients with imported malaria 
Symptoms 
11 1 patients N ("A) 
W H O  Criteria 
53 patients 
~ 
N 
Fever >38.5 "C 
Chius 
Headaches 
89 (80) Body temperature >40 "C 39 
67 (58) Parasitemia > 5% 11 
72 (63) Bilirubinema >SO pniol/L o r  jaundice 13 
Nausea/vomting 52 (45) Consciousness impairment 10 
Sweats 51 (44) Systolic blood pressure <70 mmHg 4 
Splenomegalia 28 (24) Pulmonary edema 2 
Myalgias/arthralgias 23 (21) Glycemia <2.2 mmol/L 2 
Abdominal pain 19 (16) Renal failure 1 
Diarrhea 18 (16) Hemoglobin < 5 g/dL 1 
Hepatomegaly 15 (13) Hemoglohinuria 1 
Hypotension < 100 mmHg 13 (11) Acidemia acidosis 1 
Impaired conciousness 10 (9) 
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months, p= lo-')), a high pal-asitemia (22454.2  versus 
0.5+0.5%, p<0.05), leucopenia (532622126 versus 
7430 k 3S96/mm3, p < 0.02), elevated transaminase 
fp<0.02), WHO gravity criteria (p<0.05), longer time 
to apyrexia (3.821.6 versus 2.2k1.2 days, p<0.01) 
and negative smear (3.421.2 versus 2.420.5 days, 
p<0.002), but not platelet count (104,368259,941 
versus 99,750k43,533/mm3, p=0.76). The only 
significant variable in niultivariate analysis, with a factor 
of 0.75, was symptom onset less than 30 days after 
return. In four cases, the diagnosis was made more than 
2 months after return, and up to 12 months in one case 
of niixed infection with P vivax. This patient had spent 
2 years in Guinea and, since his return, routinely took 
chloroquine when he felt any discomfort. 
Parasitemia 
Parasitemia > 5% was associated in monovariate analysis 
with platelets >50,000/iiim3 (p< WHO gravity 
criteria (p<0.01), systolic blood pressure < 10 mmHg 
(p<0.03), bilirubinemia >50 pmol/L (p<0.05), 
CKP>l00  mg/L (p<0.05), and Pjalciprum (p<O.O5), 
but not with fever and prophylaxis use. N o  differ- 
ence in clinical presentation, including WHO gravity 
criteria, was noted in 36 patients with parasitemia 
< 1 /1000. Three independent factors were determined: 
platelet count < 50,000/mm3, systolic blood pressure 
<10 mmHg and bilirubinemia >50 pmol/L with 
respective factors of 0.69, 0.47 and 0.43. 
Therapy and outcome 
Most patients received intravenous quinine (mean 
dosage 1.5620.23 g/day for 3.46k1.5 days) or oral 
mefloquine (Table 4). Fourteen were admitted to the 
ICU. Quinine was used in vomiting patients or 
when l? fakiparum parasitemia was higher than 3%. 
Exchange transfusion was additionally pelformed in 
three patients with parasitemia > 10% and aggravating 
Table 3 Admission biological data in 11 1 patients with 
imported malaria 
Parameter No. patients/No. tested (%) 
C-reactive protein >8 ml/L 
Platelets < 150,000/mm3 
Bilirubin > 10 pmol/L 
Lymphocytes < 1000/mm3 
Hemoglobin >12 g/dL 
Transaminases > 1.5 x norm 
Leukocytes <3500/mnx3 
Urea >7 mmol/L 
Creatinine > 120 pmol/L 
Glyceniia <3.6 mmol/L 
Natrenlia < 130 Meq/L 
<50,000/mm3 
70/70 (100) 
Y5/111 (85.6) 
21/111 (18.9) 
62/104 (59.6) 
25/51 (49.0) 
35/111 (31.5) 
28/109 (25.7) 
21/109 (19.3) 
16/111 (14.4) 
9/103 (8.7) 
5/111 (4.5) 
12/111 (10.8) 
Table 4 Therapy and adverse reactions in 11  1 patients 
with imported malaria 
Therapy N Adverse drug reaction ( M )  
Quinine 58 
Including 7 with additional 
doxycycline 
Mefloquine 45 
Sulfadoxindpyrimethanline 1 
Halofantrine 3 
Additional exchange transfusion 3 
Chloroquine 1 
Auditory troubles (n=2) 
Seizures, renal failure, 
hypoglycemia, myoclonia, 
vertigo (n= I each) 
Voiiiiting (ri=h) 
Auditory troubles (n=2) 
Seizures (n= 1) 
Confusion (n=1) 
Voiniting (n=1) 
clinical condition despite quinine. Two patients, present- 
ing with rapidly evolving cerebral malaria despite early 
diagnosis and high-dose intravenous quinine, died. 
None received exchange transfusions. 
An increase in parasitemia (mean +2.5%) was noted 
in 16/82 patients the day following treatment initiation. 
Platelet count was lower (mean -21,744/mm3) at day 
2 or 3 in 47/80 patients and fever was higher at  day 2 
(mean +1 "C) in 20/110 patients. These anomalies 
resolved in 1 to 4 days. 
DISCUSSION 
Estimation of malaria attack rate, cheiiioprophylaxis use 
and compliance is difficult without travel statistics and 
drug dosages. It is estimated that 50% of patients use 
effective chemoprophylaxis [8,9]. It has been suggested 
that chemoprophylaxis was associated with less frequent 
severe malaria and delay in presentation [8], and could 
lower parasitemia or modify parasite morphology [lo]. 
However, like another report [ l l ] ,  we found that 
prophylaxis, even adjusted for compliance, did not 
modify clinical presentation or mean parasitemia. 
Twelve (11%) patients were initially treated for a 
mistaken diagnosis. Most of them were receiving 
chemopi-ophylaxis, probably Ieading their physician to 
rule out malaria. A diagnosis delay in patients consulting 
their family physician or using self-medication has been 
previously reported [12]. Most of our patients came 
from chloroquine-resistant areas and used chloroquine 
alone or in combination with proguanil, a regimen 
offering imperfect protection (131. Only one took 
mefloquine, but with a low compliance. This drug is 
currently recommended for travelers to areas of endemic 
chloroquine resistance [14]. The prevalence of P 
fakiparum has been noted in previous studies on African 
travel [4,11,15-171, except for one study on US troops 
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based in Somalia [18]. The frequency of clinical 
symptoms we report is consistent with these studies, 
including a high frequency of gastrointestinal symp- 
toms. Biological abnormalities are usual during 
malaria. Thrombocytopenia [11,16,17] is frequent, and 
is independently correlated with parasitemia. When 
measured, C R P  was always elevated. Furthermore, 
C R P  >I00  mg/L was correlated with a high 
parasitemia in nionovariate analysis. C R P  increase 
during malaria attacks has been previously reported 
[19], as has a significant correlation with parasitemia 
[20]. A normal value of C R P  and/or platelets could be 
a good indicator of a non-malaria-related illness in 
patients with travel-associated fever. A study reported a 
high positive predictive value in differentiating malaria 
from viral infection using the conibination of platelet 
count and plasma bilirubin, however, 14.6% of these 
patients had neither thrombocytopenia nor hyper- 
bilirubinemia 1211. In our series, elevated C R P  and/or 
thrombocytopenia was always observed in cases of 
nialaria. It might be possible to enhance the specificity 
of this couple by defining threshold values. 
The proportion of tourists and expatriates is similar 
to the one observed in Britain in 1988 1221. Few studies 
have assessed malaria in expatriates. A study of 35 
French expatriates found similar frequencies of clinical 
signs at  adniission [23]. Lack of chemoprophylaxis in 
American expatriates in Uganda was found to be the 
highest malaria risk fx to r  1241. 
An increase of parasitemia in the first 24 h was 
observed in 20% of our patients. It is a known feature 
of malaria [3] and should not, alone, justify a change of 
therapy. We observed few adverse effects, some of them 
probably related to malaria rather than therapy. Malaria 
mortality is still around 1%, due to Pfukiparum 1221. 
Most deaths are related to delay in diagnosis and 
treatment 1251, emphasizing the need for increased 
medical knowledge and tourist caution. 
Intervention possibilities through Continuing 
Medical Education are limited. A telephone/on-line 
24-h hot line could be a powerful tool. Providing 
information to travel professionals through mailed 
leaflets could increase the number ofwould-be travelers 
seeking medical advice. Prevention will nevertheless 
remain difficult, above all in subgroups who cannot 
receive mefloquine (pregnant women, patients with 
heart conditions). For expatriates with limited access 
to medical care, standby treatment could be a solution. 
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